Saturday 17 October 2026
Export WHWK’s income statement to Excel — free account
Whitehawk Therapeutics, Inc.
WHWK Healthcare Biotechnology
Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024. In the quarter to June 2026, revenue grew 33.5%, EPS grew 73.7% and free cash flow grew 72.6%, each against the same quarter a year earlier.
2.89
0.15
−4.93%
Follow WHWK
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 4 | — | — | — | — | — | — |
P/E ratio |
5.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
P/S ratio |
5.39 | 3.29 | 2.27 | 18.21 | 307.88 | 2.56 | — | 0.00 | — | — |
Altman Z-Score |
1.52 | (5.80) | (2.36) | 5.17 | 3.46 | (2.10) | — | 4.58 | — | — |
Altman Z″-Score (non-manufacturers) |
2.98 | (14.66) | (1.35) | 6.29 | 4.63 | (10.94) | — | 10.06 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Beneish M-Score |
— | (2.58) | (1.57) | — | — | — | — | — | — | — |
P/Operating CF |
(8.69) | (5.67) | (5.72) | (24.50) | (17.34) | (11.41) | — | (9.33) | — | — |
P/B ratio |
1.10 | 1.63 | 0.52 | 1.75 | 1.58 | 0.00 | — | 0.98 | — | — |
Price to Tangible BV |
1.13 | 1.75 | 0.54 | 1.79 | 1.63 | 0.00 | — | 0.98 | — | — |
EV/Sales |
0.19 | 1.51 | (2.16) | 6.94 | 96.61 | 2.33 | — | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.70 | 0.00 | 0.00 | 0.00 | — | 0.44 | — | — |
EV/Operating CF |
(0.05) | (0.66) | 0.88 | (2.13) | (3.02) | (2.68) | — | 0.84 | — | — |
EV/FCF |
(0.05) | (0.64) | 0.83 | (2.11) | (3.00) | (2.67) | — | 0.84 | — | — |
Quick Ratio |
10.03 | 3.11 | 4.33 | 9.26 | 9.76 | 0.62 | 11.56 | 11.47 | 5.64 | 0.11 |
Current Ratio |
10.26 | 3.59 | 4.72 | 9.56 | 9.90 | 0.62 | 11.87 | 11.73 | 5.82 | 0.15 |
Net Debt/EBITDA |
1.26 | 0.69 | 1.45 | 2.88 | 4.03 | 1.32 | 1.58 | 5.62 | 0.95 | 0.10 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.85% | 0.17% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.09) | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.06 | 0.26 | 0.15 | 0.09 | 0.01 | 0.50 | 0.00 | 0.47 | 0.00 | 0.00 |
Operating CF/Net income |
4.73 | 0.94 | 0.91 | 0.82 | 0.20 | 2.84 | 1.03 | 0.56 | 0.85 | 0.75 |
Capex/Depreciation |
0.38 | 1.49 | 1.34 | (0.17) | 0.00 | (2.11) | (3.10) | (0.81) | (0.07) | (0.44) |
Interest Coverage |
— | (438.04) | (311.40) | (272.53) | (167.24) | (3.13) | (23.71) | — | — | (34.50) |
| (21.82%) | (80.79%) | (49.90%) | (41.06%) | (178.65%) | (37.05%) | (48.89%) | (27.32%) | 64.97% | 48.40% | |
| (18.63%) | (62.83%) | (41.54%) | (35.37%) | (125.31%) | (15.20%) | (44.73%) | (24.42%) | (190.77%) | (1,731.56%) | |
ROIC |
0.00% | (804.45%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(15.31%) | (124.74%) | (63.85%) | (37.42%) | (81.39%) | 39.33% | (63.93%) | (17.73%) | (128.31%) | 167.54% |
Average Days of Receivables |
0.00 | 82.92 | 82.25 | 44.67 | 0.00 | 354.21 | — | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
1,273.10% | 196.40% | 200.91% | 214.66% | 1,756.25% | 102.94% | 0.00% | 88.57% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
417.38% | 141.43% | 182.92% | 264.04% | 1,652.77% | 14.55% | 0.00% | 66.90% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
138.18% | 41.72% | 49.08% | 63.37% | 188.04% | 0.95% | 0.00% | 17.03% | 0.00% | 0.00% |
Graham Net Nets |
0.90 | 0.51 | 1.76 | 0.56 | 0.60 | (0.34) | — | 1.01 | — | — |
Graham Number |
4.88 | 0.00 | 0.00 | 0.00 | 0.00 | 12.40 | — | 0.00 | — | — |
Earnings Yield |
19.83% | (74.37%) | (119.02%) | (22.18%) | (52.58%) | (9.51%) | — | (24.69%) | — | — |
Free Cash Flow Yield |
(65.43%) | (71.66%) | (115.32%) | (18.07%) | (10.44%) | (34.09%) | — | (10.13%) | — | — |
Revenue per Share |
0.12 | 0.96 | 0.90 | 0.68 | 0.13 | 5.74 | 0.00 | 8.91 | 0.00 | 0.00 |
Operating CF per Share |
(1.57) | (2.20) | (2.22) | (2.21) | (2.51) | (5.00) | (8.81) | (2.57) | (13.06) | (276.24) |
Capex per Share |
(0.01) | (0.06) | (0.15) | (0.02) | (0.01) | (0.01) | (0.09) | (0.02) | (0.01) | (1.99) |
Free Cash Flow per Share |
(1.58) | (2.26) | (2.36) | (2.22) | (2.52) | (5.00) | (8.90) | (2.58) | (13.07) | (278.23) |
Cash per Share |
2.35 | 1.75 | 4.04 | 7.67 | 16.70 | 1.75 | 14.23 | 27.67 | 14.02 | 29.17 |
Shareholders Equity per Share |
2.20 | 1.94 | 3.91 | 7.04 | 15.29 | (4.89) | 13.50 | 25.92 | 12.06 | (1,515.27) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.20 | 1.94 | 3.91 | 7.04 | 15.29 | (4.89) | 13.50 | 25.92 | 12.06 | (1,515.27) |
Free Cash Flow |
(97.98) | (61.20) | (63.63) | (50.08) | (22.47) | (12.72) | (24.09) | (5.85) | (18.89) | (15.83) |
Working Capital |
134.49 | 44.21 | 98.19 | 161.19 | 136.00 | (11.37) | 36.24 | 58.53 | 17.31 | (12.63) |
Capital Expenditures |
(0.55) | (1.65) | (3.97) | (0.44) | (0.05) | (0.02) | (0.24) | (0.04) | (0.01) | (0.11) |
Net Current Asset Value |
134.49 | 43.45 | 97.36 | 154.17 | 129.77 | (12.57) | 36.17 | 58.53 | 17.31 | (86.39) |
EV/EBIT |
0.00 | 0.00 | 0.73 | 0.00 | 0.00 | 0.00 | — | 0.44 | — | — |
Capex to Sales |
0.08 | 0.06 | 0.16 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(482.67) | (0.16) | (0.62) | 5.25 | 1,302.82 | 0.43 | 0.47 | 0.47 | 1.18 | 1.73 |
Cash ROIC |
(34.75%) | (61.38%) | (29.73%) | (15.13%) | (7.87%) | 185.02% | (32.06%) | (4.82%) | (50.11%) | 18.72% |
Accounts Receivable Turnover |
0.00 | 4.56 | 6.63 | 1.90 | 0.00 | 2.06 | — | 0.00 | — | 0.00 |
Accounts Payable Turnover |
0.49 | 0.75 | 0.60 | 0.27 | 0.00 | 0.00 | 0.02 | 0.00 | 0.02 | 0.06 |
Inventory Turnover |
0.00 | 0.52 | 0.68 | 0.00 | — | — | 0.00 | — | 0.00 | 0.00 |
Average Days of Payables |
440.40 | 260.59 | 766.38 | 962.12 | 0.00 | 0.00 | 15,418.27 | 0.00 | 25,558.54 | 12,939.96 |
Days of Inventory on Hand |
0.00 | 641.04 | 835.12 | 508.81 | — | — | 0.00 | — | 0.00 | 0.00 |
Average Receivables |
— | 5.70 | 3.68 | 8.01 | — | 7.08 | — | — | — | 7.08 |
Average Payables |
1.54 | 4.03 | 4.71 | 4.98 | 4.42 | 2.81 | 4.34 | 4.52 | 3.03 | 1.24 |
Average Inventory |
— | 5.87 | 4.14 | — | — | — | — | — | — | — |
Average Assets |
110.57 | 101.37 | 158.33 | 171.07 | 88.37 | 29.38 | 52.03 | 42.58 | 11.71 | 1.21 |
Average Common Equity |
94.39 | 78.84 | 131.79 | 147.39 | 61.99 | 12.05 | 47.60 | 38.05 | (34.39) | (43.20) |
Columns are period end dates